Title:
CHIMERIC RECEPTOR FOR IMPROVING KILLING ACTIVITY OF IMMUNE CELLS AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/197437
Kind Code:
A1
Abstract:
The present invention belongs to the field of biological medicines, and particularly relates to a chimeric receptor for improving the killing activity of immune cells and an application thereof. Specifically, the present invention provides a fusion protein. The fusion protein comprises an extracellular part, an extracellular hinge region, a transmembrane region, and an intracellular region. Most preferably, the amino acid sequence of the fusion protein of the present invention is formed by sequentially connecting SEQ ID NO.: 1, SEQ ID NO.: 3, SEQ ID NO.: 5, SEQ ID NO.: 7, SEQ ID NO.: 9 and SEQ ID NO.: 11, and the immune cells expressing the fusion protein have strong killing activity.
Inventors:
WU LIDA (CN)
GU YUCHUN (CN)
GU YUCHUN (CN)
Application Number:
PCT/CN2022/098848
Publication Date:
October 19, 2023
Filing Date:
June 15, 2022
Export Citation:
Assignee:
ALLIFE MEDICINE（BEIJING）LIMITED (CN)
International Classes:
C07K19/00; A61K35/17; A61K39/395; A61P3/00; A61P35/00; A61P37/02; A61P39/06; C12N5/10; C12N15/62; C12N15/867
Domestic Patent References:
| WO2022032864A1 | 2022-02-17 | |||
| WO2021260696A1 | 2021-12-30 |
Foreign References:
| CN111556756A | 2020-08-18 | |||
| CN111556892A | 2020-08-18 | |||
| CN113583139A | 2021-11-02 | |||
| CN114478806A | 2022-05-13 |
Attorney, Agent or Firm:
BEIJING ZHI CHENG HAN FANG IP AGENCY CO., LTD. (CN)
Download PDF: